Navigation Links
OncoSec Medical Announces $7.2 Million Public Offering
Date:12/13/2012

SAN DIEGO, Dec. 13, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $7.2 million of securities in a registered public offering. OncoSec has agreed to sell to institutional investors an aggregate of 28,800,000 shares of its common stock at $0.25 per share. Additionally, investors will receive warrants to purchase up to 14,400,000 shares of common stock at an exercise price of $0.26 per share for a term of four years.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The gross proceeds of the offering are expected to be approximately $7.2 million. Net proceeds, after deducting the placement agent's fee and other estimated offering expenses payable by OncoSec, are expected to be approximately $6.5 million.

OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.

Dawson James Securities, Inc. acted as the exclusive placement agent for the transaction.  Burrill LLC and Noble Financial Capital Markets acted as financial advisors to OncoSec in connection with the transaction.

The offering is expected to close on December 17, 2012, subject to customary closing conditions.

The securities described above are being offered by OncoSec pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission, or the SEC. A prospectus supplement related to the offering will be filed with the SEC. The securities may only be offered by means of a prospectus. Copies of the prospectus and prospectus supplement can be obtained directly from OncoSec and at the
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Nuclear medicine market is estimated to ... Nuclear are drugs that contain radionuclide-emitting ionization radiation, ... and treat diseases. Increasing incidences of ... and ready availability of radiopharmaceuticals are the major ... awareness and use of SPECT and PET also ...
(Date:9/23/2014)...  SI-BONE, Inc., a medical device company that pioneered ... a minimally invasive surgical (MIS) device indicated for fusion ... U.S. Patent and Trademark Office has awarded the company ... fixation and fusion of bone.  This newly issued patent ... may be placed from one bone across a joint ...
(Date:9/23/2014)... , Sept. 23, 2014   LabStyle Innovations ... Diabetes Management Solution, today announced that it has ... of shares of preferred stock and warrants.  No ... estimated offering expenses, LabStyle expects to secure net ... LabStyle intends to use the ...
Breaking Medicine Technology:Global Nuclear Medicine Market - Growth, Trends & Forecasts (2014-2019) 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5
... Use of,a low profile PressureWire yields a ... to catheter-derived pressure gradient,(CPG) measurements, according to a ... Vol. 20, Issue 1: 63-65)., The authors ... a,catheter and PressureWire correlated with anatomic stenosis, PressureWire,gradient ...
... 27 Puroast(R) Low Acid Coffee,has conducted both ... its great tasting, gourmet coffee provides symptom relief ... brew. Puroast(R) achieves,this without extractions, substitutes or additives; ... full-bodied taste., Prior chemistry research at University ...
Cached Medicine Technology:Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 2Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 3Low Acid Coffee Backed By Scientific Research 2
(Date:9/23/2014)... 23, 2014 Florida Hospital Zephyrhills ... renovated Women’s Health Center on Wednesday, September 24. ... the specially designed center offers a new level ... County. The Women’s Health Center offers comprehensive women’s ... labor and delivery through The Baby Place®, and ...
(Date:9/23/2014)... "The primary purpose of the CALL LIGHT CADDY is patient ... "Call lights are often found on the floor, lost in ... out of the patient's reach. In order to make sure ... it, I created this caddy." , She developed the CALL ... easy reach. The accessory ensures that the call device can ...
(Date:9/23/2014)... A new analysis of published studies found that ... cancer versus benign disease in regions where infections ... of lung lesions suspicious for cancer could lead ... additional potential complications and mortality. , Histoplasmosis ... that are often concentrated in bird droppings and ...
(Date:9/23/2014)... NIH TO CONVENE PATHWAYS TO PREVENTION WORKSHOP: ROLE OF ... WHAT: , The National Institutes of Health is ... available scientific evidence on the long-term effectiveness and potential ... be among the nation,s top experts in the field ... as well as key NIH scientists who focus on ...
(Date:9/23/2014)... The University of California, Davis, and Academia Sinica, ... China (Taiwan), have entered into a collaborative agreement ... program that couples cutting-edge research with opportunities to ... new companies. , The agreement was signed Sept.12 ... research at UC Davis and President Chi-Huey Wong ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 3Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2
... rehabilitation professionals expect 20-plus percent employment increases through 2016. ... ... September 8, 2008 -- People reach significant milestones through ... the http://www.nraf-rehabnet.org/ [National Rehabilitation Awareness Foundation], which ...
... Common painkillers like aspirin and ibuprofen appear to lower a ... to help gauge whether a man is at risk of ... appears online Sept. 8 in the journal Cancer , ... to prevent prostate cancer just yet. , "We showed ...
... Pa., Sept. 5 Lieutenant Governor,Catherine Baker Knoll today ... Blood Donor Day., The Commonwealth of Pennsylvania and ... to give blood in commemoration of those who lost ... supplies. One blood,donation can save up to three lives., ...
... John McCain to commit to develop a National AIDS,Strategy ... Sep. 5 The,Republican National Convention concluded last night ... United States and only passing reference to,the epidemic overseas. ... Gov. Sarah Palin mentioned AIDS in their remarks,to Convention ...
... 5 On Saturday, September 6, PARI,Respiratory Equipment will ... part of their "Breathe Easier" series. PARI is highlighted ... as COPD,sufferers, with effective nebulizers and compressors that deliver ... to improve the lives of those affected by respiratory,diseases ...
... disease resistance to anti-hormonal therapy , , FRIDAY, Sept. ... help "re-sensitize" certain breast cancer tumors to anti-hormonal ... , Women with estrogen-receptor or progesterone-receptor positive (ER ... anti-hormonal medicines, such as aromatase inhibitors, to keep ...
Cached Medicine News:Health News:U.S. Demand for Rehabilitation Professionals Grows 2Health News:U.S. Demand for Rehabilitation Professionals Grows 3Health News:Common painkillers lower levels of prostate cancer biomarker 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3Health News:PARI Respiratory Equipment Featured on Oxygen Network 2Health News:Drug Re-Sensitizes Breast Tumors to Treatment 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: